MedTrace Logo

Effect of Dexlansoprazole on Bone Homeostasis

NCT01216293 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2024-03-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effect of dexlansoprazole modified release (MR), once daily (QD), on bone homeostasis.

Conditions

  • Homeostasis
  • Bone and Bones

Interventions

DRUG

Dexlansoprazole

Dexlansoprazole 60 mg capsules

DRUG

Esomeprazole

Esomeprazole 40 mg capsules

DRUG

Placebo

Placebo-matching capsules

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-01
Primary Completion
2014-08-01
Completion
2015-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01216293 on ClinicalTrials.gov